TY - JOUR T1 - Metastatic disease from uveal melanoma: treatment options and future prospects JF - British Journal of Ophthalmology JO - Br J Ophthalmol SP - 38 LP - 44 DO - 10.1136/bjophthalmol-2016-309034 VL - 101 IS - 1 AU - Richard D Carvajal AU - Gary K Schwartz AU - Tongalp Tezel AU - Brian Marr AU - Jasmine H Francis AU - Paul D Nathan Y1 - 2017/01/01 UR - http://bjo.bmj.com/content/101/1/38.abstract N2 - Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localised to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little published evidence for the optimal management and treatment of metastatic uveal melanoma and the lack of effective therapies in this setting has led to the widespread use of systemic treatments for patients with cutaneous melanoma. Uveal and cutaneous melanomas are intrinsically different diseases and so dedicated management strategies and therapies for uveal melanoma are much needed. This review explores the biology of uveal melanoma and how this relates to ongoing trials of targeted therapies in the metastatic disease setting. In addition, we consider the options to optimise patient management and care. ER -